We observed that NCI-H69 SCLC tumor xenografts chronically exposed in vivo to Cisplatin developed a 5-fold resistance to Cisplatin in association with overexpression of TRIB2 and downregulation of CEBPA, leading to enhanced proliferation and cell survival in the presence of the cytotoxic agent; further, that sensitivity could be restored at least partially by knocking down TRIB2, which results in CEBPA induction, or treatment with a cyclin-dependent kinase inhibitor, flavopiridol. The gene discussed is TRIB2; the disease is small cell lung carcinoma.